Lindab International AB (publ) (STO:LIAB)
Sweden flag Sweden · Delayed Price · Currency is SEK
119.60
+1.10 (0.93%)
Jul 24, 2026, 5:29 PM CET

Lindab International AB Earnings Call Transcripts

Fiscal Year 2026

  • Net sales grew 2% in Q2 2026, with margin pressure from higher costs and geopolitical disruptions. Profile Systems returned to growth, while Western Europe remained weak. Outlook for 2026 is flat, with recovery expected in 2027, and technical ventilation segments showing strong momentum.

  • Group sales declined year-over-year due to currency effects and weak Profile Systems results, while Ventilation Systems maintained stability and improved margins. The company expects slow market recovery in 2026, with ongoing restructuring and price increases to offset rising costs.

Fiscal Year 2025

  • Adjusted operating profit and margins improved year-over-year, led by Ventilation Systems and efficiency measures. Profile Systems continued to face challenges, but divestments and restructuring are underway. Market outlook is cautiously optimistic, with growth expected in 2026.

  • Ventilation Systems delivered record Q3 results, driven by efficiency gains and acquisitions, while Profile Systems continued to face challenges in Sweden. Strong cash flow and stable leverage support ongoing structural measures and targeted acquisitions, with market recovery expected in 2026.

  • Ventilation Systems delivered strong margins despite weak markets, while Profile Systems struggled with low volumes and project delays. Efficiency measures, divestments, and acquisitions position the group for future growth, with stabilization expected in H2 2025.

  • Q1 2025 delivered record sales in Ventilation Systems and stable group EBIT, despite challenging markets and negative organic growth. Cost reduction and divestment programs are on track, with acquisitions continuing to drive growth. Margin targets remain, contingent on H2 market recovery.

  • Pre-Close Call

    Ventilation market volumes declined 5% through Q3 2024, with recovery expected in H2 2025. Cost-saving actions, site closures, and workforce reductions are underway, while strong cash flow supports ongoing acquisitions and strategic focus on ventilation.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018

Fiscal Year 2017